Ibrutinib and novel BTK inhibitors in clinical development

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinleye, Akintunde, Chen, Yamei, Mukhi, Nikhil, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751776/
https://www.ncbi.nlm.nih.gov/pubmed/23958373
http://dx.doi.org/10.1186/1756-8722-6-59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751776/
https://www.ncbi.nlm.nih.gov/pubmed/23958373
http://dx.doi.org/10.1186/1756-8722-6-59

Ejemplares similares